Autism spectrum disorder
Drug research and approvals for autism spectrum disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 349 studies of autism spectrum disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 349
- Trials authorized in Canada: 18
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 349 recruiting on ClinicalTrials.gov ↗- Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion DysregulationNCT07624448 · Not applicable · Children's Mercy Hospital Kansas City · starts Oct 1, 2027
- Transcranial Direct Current Stimulation in Children With AutismNCT07092280 · Not applicable · New York State Institute for Basic Research · starts Nov 25, 2026
- Effects of Transcranial Direct Current Stimulation for Enhancing Cognitive Function in Individuals With Autism Spectrum…NCT07931781 · Not applicable · The Hong Kong Polytechnic University · starts Nov 16, 2026
- Effectiveness of Clown Therapy in Facilitating Dental Visits for Children With Autism Spectrum DisorderNCT07906288 · Not applicable · University of Milan · starts Nov 10, 2026
- Heart Rate Variability Biofeedback for Anxiety in Autistic YouthNCT07812233 · Phase 2 · Massachusetts General Hospital · starts Oct 26, 2026
- Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in…NCT07903675 · Not reported · Schweitzer Engineering Laboratories · starts Oct 23, 2026
- Semaglutide in Youth With Autism Spectrum DisorderNCT07770152 · Phase 4 · Children's Hospital Medical Center, Cincinnati · starts Oct 18, 2026
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismNCT07284745 · Phase 3 · Bristol-Myers Squibb · starts Oct 6, 2026
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNCT07285798 · Phase 3 · Bristol-Myers Squibb · starts Oct 6, 2026
- A Comparative Study of Driving Performance Among Adolescents With Autism Spectrum Disorder and Neurotypical AdolescentsNCT07630298 · Not applicable · Hopital La Musse · starts Oct 5, 2026
Trials Authorized in Canada
The 10 newest of 18; search them all in Canada trials| Aug 19, 2026 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability, and pharmacokinetics of karxt +…XANOMELINE-TROSPIUM (KARXT, BMS-986510) / XANOMELINE (KARXT-EC, BMS-986519) | Bristol-Myers Squibb | Pending |
| Apr 2, 2026 | A randomized, placebo-controlled trial of ppf3 vs. placebo in the treatment of children and adolescents with neurodevelopmental disordersPPF3 | HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL | Pending |
| Mar 27, 2024 | Psilocybin for treatment-resistant depression in autism: a pilot trial with pre-post brain and cognitive measurement to understand mechanisms (pat-da)PSILOCYBIN (PEX010) | CENTRE FOR ADDICTION AND MENTAL HEALTH | Ongoing |
| Oct 19, 2023 | An open-label extension study to investigate safety and tolerability of ml-004 in adolescents and adults with autism spectrum disorder (asd)ZOLMITRIPTAN (ML-004) | MAPLIGHT THERAPEUTICS, INC. | Ongoing |
| Dec 23, 2021 | A randomized, double-blind, parallel group, placebo-controlled study to investigate the efficacy, safety, and tolerability of ml-004 in adolescents and adults…ZOLMITRIPTAN (ML-004) | MAPLIGHT THERAPEUTICS, INC. | Closed |
| Aug 17, 2021 | Imaging alterations in synaptic density in autism spectrum disorder using a novel synaptic vesicular protein 2a tracer [18f]synvest-1[F-18]SDM-8 | CENTRE FOR ADDICTION AND MENTAL HEALTH | Ongoing |
| May 26, 2021 | An exploratory, phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (gwp42003p;…CANNABIS (CANNABIDIOL;GWP42003-P) | GW RESEARCH LIMITED | Closed |
| Mar 16, 2021 | A randomized placebo-controlled trial of sertraline vs. placebo in the treatment of anxiety in children and adolescents with neurodevelopmental disordersSERTRALINE | DR EVDOKIA ANAGNOSTOU | Ongoing |
| Jul 10, 2020 | A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and…ALOGABAT (RO7017773) | Roche | Closed |
| May 7, 2019 | Deep brain stimulation for the treatment of refractory repetitive self-injurious behaviour in children with autism spectrum disorder. a pilot project.GLUCOVISION ([F18]-FDG PHOSPHATE, [F18]-FDG CITRATE) | THE HOSPITAL FOR SICK CHILDREN | Ongoing |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 20, 2018 | Slenytomelatonin | RAD Neurim Pharmaceuticals EEC SARL | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA